VRTX vs VTVT
VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief. VTVT: vTv Therapeutics is a late-stage biopharma company developing novel, oral treatments for diabetes and chronic diseases, highlighted by its Phase 3 lead candidate for type 1 diabetes.
Side-by-side fundamentals
| Metric | VRTX | VTVT | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $514.65 | $27.85 | |
| Market cap | $130.4B | $110M | |
| P/E as of 2026-10-20 | 29.97 | n/a | |
| Net margin FY2025, SEC XBRL | +32.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +34.8% | n/a | |
| ROE FY2025, SEC XBRL | +21.2% | -41.9% | VRTX higher |
| ROA FY2025, SEC XBRL | +15.4% | -30.0% | VRTX higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +10.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.46 | 1.03 | |
| 1-year return as of 2026-10-20 close | +22.8% | +35.1% | VTVT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.